Login to MyKarger

New to MyKarger? Click here to sign up.

Login with Facebook

Forgot Password? Reset your password

Authors, Editors, Reviewers

For Manuscript Submission, Check or Review Login please go to Submission Websites List.

Submission Websites List

Institutional Login (Shibboleth)

For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.

Table of Contents
Vol. 1, No. 4-5, 2004
Issue release date: November 2004
Section title: Paper
Neurodegenerative Dis 2004;1:168–174

BACE1 and Presenilin: Two Unusual Aspartyl Proteases Involved in Alzheimer’s Disease

Dominguez D.-I. · Hartmann D. · De Strooper B.
Neuronal Cell Biology and Gene Transfer Laboratory, Department of Human Genetics, KU Leuven and VIB4, Leuven, Belgium
email Corresponding Author

Diana-Ines Dominguez

Molecular Genetics Section, VIB4, Departement Menselijke Erfelijkheid, O. & N.

Herestraat 49, bus 602, BE–3000 Leuven (Belgium)

Tel. +32 16 345878, Fax +32 16 347181

E-Mail Diana-Ines.Dominguez@med.kuleuven.ac.be

Do you have an account?

Login Information

Contact Information

I have read the Karger Terms and Conditions and agree.


Two enzymatic activities are required to generate the pathogenic β-amyloid (Aβ) peptide that accumulates in the brain of Alzheimer’s disease patients. Both activities are carried out by two unusual aspartyl proteases known as β- and γ-secretase. Their therapeutic inhibition appears, therefore, a promising strategy to treat the disease. Transgenic mouse models in which the genes encoding the secretases have been ablated offer an invaluable tool, on the one hand, to gain more insights into the biological function of these proteases and, on the other hand, to predict the consequences that might be associated with enzyme inhibition in vivo.

© 2004 S. Karger AG, Basel

Article / Publication Details

First-Page Preview
Abstract of Paper

Published online: November 15, 2004
Issue release date: November 2004

Number of Print Pages: 7
Number of Figures: 0
Number of Tables: 0

ISSN: 1660-2854 (Print)
eISSN: 1660-2862 (Online)

For additional information: http://www.karger.com/NDD

Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.